

16 October 2017

To the Press and to whom it may concern

EFPIA Japan  
(European Federation of Pharmaceutical Industries and Associations)

## **EFPIA Japan Patient Organization Support Program “PASE” First ever “PASE AWARD” winners decided**

EFPIA Japan (European Federation of Pharmaceutical Industries and Associations) has made its first ever PASE AWARDS, selecting patient groups that particularly contribute to the evolution of Japan’s patient advocacy and offering grants totaling 1.15 million yen. These grants have been made as part of “PASE (Patient Advocacy Support by EFPIA Japan (hereinafter, ‘PASE’))”, which was established this July. This year the “Grand Award” has been given to two groups, and the “Honor Award” has been given to three groups, after a rigorous review of the proposals and activities of the total 29 groups that applied to this program.

### **PASE AWARD winning organizations**

<b>Award</b>	<b>Award winning organization</b>	<b>Overview of application/proposal</b>	<b>Grant</b>
Grand Award	CSR Project	Conduct a patient survey with the aim of providing information to establish support for the balance of work and cancer treatments	500,000 JPY
Grand Award	Clavis Arcus	Launch an organization that unifies parties affected by genomic medicine and organize disease awareness activities.	500,000 JPY
Honor Award	Advocacy Association of Allergic Patients	Organize patient support events with the goal of raising health literacy and providing self-management skills	50,000 JPY
Honor Award	One Step	Facilitate patient education activities about how to establish	50,000 JPY

---

EFPIA Japan

Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265  
Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

		a sustainable universal healthcare system	
Honor Award	Japan IDDM network	Evaluate the social impact of the Bionic Artificial Pancreas Transplantation Project	50,000 JPY

Ole Mølsov Bech, Chairman of EFPIA Japan, who sat on the selection committee of the first PASE AWARDS, said: "I would like to express our appreciation to all the organizations that participated in our very first PASE AWARDS program. Selecting the winners of the Grand Award was extremely challenging because the activities of all the patient organizations that applied were diverse in terms of disease areas and scale. I was very impressed and assured by how each group plays an important role in Japanese healthcare society. I hope EFPIA Japan and all the patient groups that applied, including the two winners of the Grand Award, can collaborate and together contribute to developing the Japanese healthcare environment."

The first PASE AWARDS invited active patient groups with legal entities to submit plans between 4 July and 31 August to utilize the PASE grant in Japan. The draft plans were reviewed and selected based on five evaluation criteria: "contribution to healthcare throughout Japan", "implementation of educational activity on the disease itself and the related countermeasures", "novelty of the proposed activity compared with past activity performances", "feasibility of the plan", and "how important is the PASE grant in the proposed plan". As a result, five out of the diverse 29 organizations were selected, and their presentations and Q&A sessions were reviewed. The PASE AWARDS final selection committee consisted of five individuals, including EFPIA Japan board members and an external senior advisor. The draft plans were scored against the evaluation criteria, and the winners of the Grand Award were decided in a fair and objective manner.

The two organizations that won the Grand Award have each been offered a grant of 500,000 yen and are invited to attend the presentation ceremony on 1 November this year. The three groups that won the Honor Award have been offered a grant of 50,000 yen and an opportunity to exchange further information with EFPIA Japan. Details of the PASE AWARDS presentation ceremony will be notified separately.

Below is the list of organizations that applied for the first PASE grants. Please visit each website to learn more about the activities of the individual organizations.

#### 2017 PASE AWARD Applicant Organizations (in no particular order)

Organization	Disease Area	URL
--------------	--------------	-----

Japan Fabry Disease patients and family association	Fabry's disease	<a href="http://www.fabrynet.jp/">http://www.fabrynet.jp/</a>
Fine	Gynecology	<a href="http://j-fine.jp/">http://j-fine.jp/</a>
Sagamihara Allergy no kai	Allergy	<a href="http://www.sagamihara-allergy.org/">http://www.sagamihara-allergy.org/</a>
Kirara (Breast cancer)	Breast cancer	<a href="http://www.nakagawak.jp/">http://www.nakagawak.jp/</a>
PID Tsubasa	Primary immunodeficiency	<a href="http://npo-pidsubasa.org/">http://npo-pidsubasa.org/</a>
CSR Project	Cancer	<a href="http://workingsurvivors.org/">http://workingsurvivors.org/</a>
XXXXXX	Intractable disease in children	Patient organization desired not to disclose their name
Cancer Support Community	Cancer	<a href="http://www.csc-japan.org/">http://www.csc-japan.org/</a>
J-BREATH	Respiratory disease	<a href="http://www.j-breath.jp/">http://www.j-breath.jp/</a>
Allergy wo kangaeru hahanokai	Allergy	<a href="http://hahanokai.org/">http://hahanokai.org/</a>
JAPAN PARKINSON'S DISEASE ASSOCIATION	Parkinson's Disease	<a href="https://sites.google.com/site/jpdaorg/">https://sites.google.com/site/jpdaorg/</a>
Association of study for Pulmonary Hypertension	Pulmonary Hypertension	<a href="http://www.aphj.org/">http://www.aphj.org/</a>
Clavis Arcus	Hereditary Breast and Ovarian Cancer	<a href="http://www.clavisarcus.com/">http://www.clavisarcus.com/</a>
JALSA, Japan Amyotrophic Lateral Sclerosis Association	ALS	<a href="http://alsjapan.org/">http://alsjapan.org/</a>
Japan IDDM network	Type 1 DM	<a href="http://japan-idm.net/">http://japan-idm.net/</a>
Japan Multiple Sclerosis Society	Neurology	<a href="http://www.jmss-s.jp/">http://www.jmss-s.jp/</a>
Nanbyou network	Intractable disease in children	<a href="https://www.nanbyonet.or.jp/">https://www.nanbyonet.or.jp/</a>
Japan Association of Medical Translation for Cancer	Cancer	<a href="https://jamt-cancer.org/">https://jamt-cancer.org/</a>
Heart -mamoru	Heart disease	<a href="http://www.heart-mamoru.jp/">http://www.heart-mamoru.jp/</a>



European Federation of Pharmaceutical  
Industries and Associations

Japan Federation of Cancer Patient Groups	Cancer	<a href="http://zenganren.jp/">http://zenganren.jp/</a>
Tourette Syndrome Association of Japan	Tourette Syndrome	<a href="http://tourette-japan.org/">http://tourette-japan.org/</a>
Advocacy Association of Allergic Patients	Allergy	<a href="https://aalp201705.wixsite.com/aalp">https://aalp201705.wixsite.com/aalp</a>
Orange tea	Gynecological cancer	<a href="http://o-tea.org/">http://o-tea.org/</a>
Registered Non Profit Organization Hospital Play Society Japan	General	<a href="http://hps-japan.net/">http://hps-japan.net/</a>
NPO Kanja Speaker Bank	General	<a href="http://npoksb.org/">http://npoksb.org/</a>
NPO Prostate Cancer Patients Association	Prostate cancer	<a href="http://pc-pc.org/">http://pc-pc.org/</a>
Expert Patient in Respiratory Care	Respiratory disease	<a href="http://www.eparec.org/">http://www.eparec.org/</a>
NPO Pancreatic Cancer Action Network Japan	Pancreatic cancer	<a href="http://www.pancan.jp/">http://www.pancan.jp/</a>
One Step	Lung cancer	<a href="http://www.lung-onestep.jp/">http://www.lung-onestep.jp/</a>

EFPIA Japan will continue to make efforts to realize “patient-centered healthcare” in Japan.

# # #

### **About the EFPIA Japan Patient Organization Support Program “PASE”**

“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program newly established with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE is designed to help further vitalize patient group activities in Japan, and supports the healthcare environment surrounding patients to evolve, so that it better reflects patients’ voices in the healthcare system.

As part of PASE, EFPIA Japan decided to conduct the PASE AWARDS, in which grants of 1.15 million yen this year will be awarded to organizations that contribute to the evolution of patient advocacy (activities to protect patient rights).

[http://efpia.jp/link/1706\\_Notifcation\\_EFPIA\\_PASE\\_JP.pdf](http://efpia.jp/link/1706_Notifcation_EFPIA_PASE_JP.pdf).

### **First PASE final selection committee**

- Ole Mølskov Bech, Chairman, EFPIA Japan (Novo Nordisk Pharma Ltd)
- Philippe Fauchet, Vice Chairman, EFPIA Japan (Glaxo SmithKline K.K.)
- Jacques Nathan, Board of Director, EFPIA Japan (Sanofi K.K.)
- Mariko Mimura, Committee Chair, Governance and Legal Committee, EFPIA Japan (Glaxo)



European Federation of Pharmaceutical  
Industries and Associations

SmithKline K.K.)

- Masuhiro Kato, Specially Appointed Professor, Translational Research Initiative, The University of Tokyo, and Senior Advisor of EFPIA Japan

### **About the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan**

EFPIA Japan, established in April 2002, represents 24 R&D-based European pharmaceutical companies operating in the Japanese market. Combined sales from the EFPIA member companies account for approximately 25% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “contribute to healthcare and patients in Japan through the rapid introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen communication with policymakers for the improvement of Japanese healthcare.

### **About the European Federation of Pharmaceutical Industries and Associations (EFPIA)**

EFPIA, headquartered in Brussels, the capital of Belgium, represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 42 leading pharmaceutical companies, EFPIA is the voice of 1,900 companies committed to developing and bringing new treatments to patients around the world that will improve the quality of life.

Details can be found below.

<http://efpia.jp/English/index-e.html> (EFPIA Japan)

<http://www.efpia.eu> (EFPIA)

### **Inquiries to:**

Noriko Okazaki, Committee Chair, Public Relations Committee, EFPIA Japan

Novo Nordisk Pharma Ltd.

2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005

TEL: 03-6266-1700

Mail: [no@novonordisk.com](mailto:no@novonordisk.com)

Yumiko Kurahashi, Public Relations Committee, EFPIA Japan

AstraZeneca K.K.

Marunouchi Trust Tower, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo 100-0005

TEL : 03-6268-3857

Mail: [Yumiko.Kurahashi@astrazeneca.com](mailto:Yumiko.Kurahashi@astrazeneca.com)